{{Drugbox
| verifiedrevid = 461093677
| IUPAC_name = (''RS'')-2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-ethane
| image = Enflurane.svg
| image2 = Enflurane-3D-balls.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|enflurane}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 97%
| metabolism =  
| elimination_half-life =
<!--Identifiers-->
| IUPHAR_ligand = 7175
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 13838-16-9
| ATC_prefix = N01
| ATC_suffix = AB04
| ATC_supplemental =  
| PubChem = 3226
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00228
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3113
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 91I69L5AY5
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00543
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4792
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1257
<!--Chemical data-->
| C=3 | H=2 | Cl=1 | F=5 | O=1
| molecular_weight = 184.492 g/mol
| smiles = FC(Cl)C(F)(F)OC(F)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JPGQOUSTVILISH-UHFFFAOYSA-N
}}
'''Enflurane''' (2-chloro-1,1,2,-trifluoroethyl-difluoromethyl ether) is a [[halogenated ether]].  Developed by [[Ross Terrell]] in 1963, it was first used clinically in 1966. It was increasingly used for inhalational [[anesthesia]] during the 1970s and 1980s<ref name="NiedermeyerSilva2005">{{cite book|last1=Niedermeyer|first1=Ernst|last2=Silva|first2=F. H. Lopes da|title=Electroencephalography: Basic Principles, Clinical Applications, and Related Fields|url=https://books.google.com/books?id=tndqYGPHQdEC&pg=PA1156|year=2005|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-5126-1|page=1156}}</ref> but is no longer in common use.

Enflurane is a structural [[isomer]] of [[isoflurane]]. It vaporizes readily, but is a liquid at room temperature.

==Physical properties==
{| class="wikitable"
! Property
! Value
|-
| [[Boiling point]] at 1 [[atmosphere (unit)|atm]]
| 56.5&nbsp;°C
|-
| [[Minimum alveolar concentration|MAC]]
| 1.68
|-
| [[Vapor pressure]] at 20&nbsp;°C
| 22.9 kPa (172 [[torr|mm Hg]])
|-
| [[Blood:gas partition coefficient]]
| 1.9
|-
| Oil:gas partition coefficient
| 98
|-
|}

==Side effects==
Clinically, enflurane produces a dose-related depression of [[myocardial]] [[contractility]] with an associated decrease in myocardial oxygen consumption. Between 2% and 5% of the inhaled dose is oxidised in the liver, producing [[fluoride]] ions and difluoromethoxy-difluoroacetic acid. This is significantly higher than the metabolism of its structural isomer [[isoflurane]].

Enflurane also lowers the threshold for [[seizures]], and should especially not be used on people with [[epilepsy]].<ref>{{Cite web|url=https://thinklab.com/discussion/prediction-in-epilepsy/224#6|title=Enflurane has established ictogenic properties?|last=|first=|date=April 2004|website=Thinklab|publisher=|access-date=October 17, 2016}}</ref>  Like all potent inhalation anaesthetic agents it is a known trigger of [[malignant hyperthermia]].

Like the other potent inhalation agents it relaxes the uterus in pregnant women which is associated with more blood loss at delivery or other procedures on the gravid uterus.

The obsolete (as an anaesthetic) agent [[methoxyflurane]] had a nephrotoxic effect and caused acute renal failure, usually attributed to the liberation of fluoride ions from its metabolism.  Enflurane is similarly metabolised but the liberation of fluoride results in a lower plasma level and enflurane related renal failure seemed unusual if seen at all.<ref>By G. Edward Morgan, Maged S. Mikhail, Michael J. Murray, C. Philip Larson; Clinical Anaesthesiology third edition,142.</ref>

==Pharmacology==
The exact mechanism of the action of general anaesthetics have not been delineated.<ref>http://www.scientificamerican.com/article/how-does-anesthesia-work/</ref>  Enflurane acts as a [[positive allosteric modulator]] of the [[GABAA receptor|GABA<sub>A</sub>]], [[glycine receptor|glycine]], and [[5-HT3 receptor|5-HT<sub>3</sub> receptor]]s,<ref name="PerryAshton2002">{{cite book|author1=Elaine K. Perry|author2=Heather Ashton|author3=Allan H. Young|title=Neurochemistry of Consciousness: Neurotransmitters in Mind|url=https://books.google.com/books?id=3o2fCDDoSuUC&pg=PA154|year=2002|publisher=John Benjamins Publishing|isbn=1-58811-124-5|pages=154–}}</ref><ref name="CoteLerman2013">{{cite book|author1=Charles J. Cote|author2=Jerrold Lerman|author3=Brian J. Anderson|title=A Practice of Anesthesia for Infants and Children: Expert Consult - Online and Print|url=https://books.google.com/books?id=MAXTnQStL0cC&pg=PA499|year=2013|publisher=Elsevier Health Sciences|isbn=1-4377-2792-1|pages=499–}}</ref> and as a [[negative allosteric modulator]] of the [[AMPA receptor|AMPA]], [[kainate receptor|kainate]], and [[NMDA receptor]]s,<ref name="CoteLerman2013" /><ref name="BarashCullen2013">{{cite book|author1=Paul Barash|author2=Bruce F. Cullen|author3=Robert K. Stoelting |author4=Michael Cahalan |author5=Christine M. Stock |author6=Rafael Ortega|title=Clinical Anesthesia, 7e: Print + Ebook with Multimedia|url=https://books.google.com/books?id=exygUxEuxnIC&pg=PA116|date=7 February 2013|publisher=Lippincott Williams & Wilkins|isbn=978-1-4698-3027-8|pages=116–}}</ref><ref name="pmid7681790">{{cite journal | vauthors = Lin LH, Chen LL, Harris RA | title = Enflurane inhibits NMDA, AMPA, and kainate-induced currents in Xenopus oocytes expressing mouse and human brain mRNA | journal = FASEB J. | volume = 7 | issue = 5 | pages = 479–85 | year = 1993 | pmid = 7681790 | doi = | url = http://www.fasebj.org/cgi/pmidlookup?view=long&pmid=7681790}}</ref> as well as of [[nicotinic acetylcholine receptor]]s.<ref name="PerryAshton2002" />

== Occupational safety ==
In the workplace, people may be exposed to enflurane by breathing it in as a waste anaesthetic gas, swallowing it, eye contact, or skin contact. The [[National Institute for Occupational Safety and Health]] (NIOSH) has set a [[recommended exposure limit]] (REL) for exposure to waste anaesthetic gas of 2 ppm (15.1&nbsp;mg/m<sup>3</sup>) over a 60-minute period. Symptoms of occupational exposure to enflurane include eye irritation, [[central nervous system depression]], [[analgesia]], [[anesthesia]], [[convulsions]], and [[respiratory depression]].<ref>{{Cite web|title = CDC - NIOSH Pocket Guide to Chemical Hazards - Enflurane|url = https://www.cdc.gov/niosh/npg/npgd0253.html|website = www.cdc.gov|accessdate = 2015-10-01}}</ref>

==References==
{{Reflist|2}}

{{General anesthetics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{GABAA receptor positive modulators}}
{{Glycine receptor modulators}}
{{Ionotropic glutamate receptor modulators}}
{{Nicotinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}

[[Category:5-HT3 agonists]]
[[Category:AMPA receptor antagonists]]
[[Category:NMDA receptor antagonists]]
[[Category:Kainate receptor antagonists]]
[[Category:General anesthetics]]
[[Category:Ethers]]
[[Category:Organochlorides]]
[[Category:Organofluorides]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Nicotinic antagonists]]
[[Category:Glycine receptor agonists]]
[[Category:Fluranes]]